TPN-672 / Jiangsu Kanion Pharma - LARVOL DELTA

Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia (clinicaltrials.gov) - P1; N=62; Not yet recruiting; Sponsor: Jiangsu Kanion Pharmaceutical Co., Ltd

Clinical • New P1 trial • CNS Disorders • Psychiatry • Schizophrenia

TPN672: A Novel Serotonin-Dopamine Activity Modulator for the Treatment of Schizophrenia. (PubMed, J Pharmacol Exp Ther) - "Significance Statement TPN672 acted as a potent 5-HTR agonist, DR/DR partial agonist and 5-HTR antagonist, displayed robust antipsychotic efficacy significantly higher than that of aripiprazole in rodent models. TPN672 is a promising new drug candidate for the treatment of schizophrenia and has been shown to be more effective in attenuating negative symptoms and cognitive deficits, meanwhile have a lower risk of EPS (Extrapyramidal symptoms) and hyperprolactinemia."

Journal • CNS Disorders • Cognitive Disorders • Mental Retardation • Psychiatry • Schizophrenia

Tolerance, PK and PD Effects Study of TPN-672 in Chinese Healthy Volunteers (clinicaltrials.gov) - P1; N=62; Recruiting; Sponsor: Shanghai Mental Health Center; Trial completion date: Feb 2020 ➔ Dec 2020; Trial primary completion date: Oct 2019 ➔ Oct 2020

Clinical • Trial completion date • Trial primary completion date • BDNF • IL2 • IL4 • IL6